|Articles|July 31, 2007

Survey: What Will You Do About Rosiglitazone (Avandia)?

Take this MedPage Today survey.

On Monday, a special FDA advisory panel recommended that rosiglitazone (Avandia) stay on the market, despite an acknowledged increase in ischemic heart risks for type 2 diabetes patients. A meta-analysis published this spring linked the drug to a 43% increase in risk of myocardial infarction.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Latest CME

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Survey: What Will You Do About Rosiglitazone (Avandia)?

Related Content

Reminders for Primary Care Physicians, Patients Improved Annual Lung Cancer Screening Adherence

Relationship-Based Navigation Improves Resource Access in Primary Care Trial

Freenome Lung Cancer Blood Test Receives FDA Breakthrough Device Status

How Primary Care Physicians Can Target Midlife Vascular Risk to Support Brain Health

New Childhood Vaccine Executive Order Draws Criticism From AAP, AMA, NFID

Latest CME

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Houston Hematology Satellite Symposia

AREDS3 and Beyond: The Scientific Basis for B Vitamin Nutritional Supplementation in AMD

Satellite Symposia at the Annual Radiation Oncology Meeting

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Arizona

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Nevada

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

24th Annual International Congress on the Future of Breast Cancer® East

25th Annual International Congress on the Future of Breast Cancer® East

25th Annual International Congress on the Future of Breast Cancer® West

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Medical Crossfire®: BPDCN in 2026—Expert Perspectives on Diagnosis, Frontline Therapy, and the Evolving CD123-Directed Pipeline

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Medical Crossfire®: Maximizing Durability Across Retinal Disease — What 3 Years of Evidence Means for Your Practice

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Kentucky

Indiana Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Arkansas Association of Cancer Professionals

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Tennessee Oncology Practice Society

Kansas Society of Clinical Oncology

EyeCon 2026

27th Annual International Lung Cancer Congress®

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Texas Society of Clinical Oncology

North Carolina Oncology Association

The Optometry Meeting in Anaheim

Jersey City Psychiatry

Louisiana Oncology Society

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

IgAN Case Files: Real Conversations, Evolving Evidence

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – North Carolina

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Washington

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Montana/Wyoming

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Tennessee

SimulatEd™: Partnering for Precision – A Framework for Personalized Care Planning in Acute Lymphoblastic Leukemia

(CME Track) Seeing the Signs: Multidisciplinary Strategies to Manage Ocular Toxicities Associated With Cancer Therapies

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Nevada

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Kentucky

Targeting the Cortisol Cascade: Diagnosis and Treatment Strategies in Patients with Hypertension

20th Annual New York Lung Cancers Symposium®

ADA-SCID Chronicles: A Journey From Screening to Successful Outcomes

Patient, Provider, and Caregiver Connection™: Individualizing Care in C3 Glomerulopathy – Understanding Patient Challenges and the Role of Innovative Treatment

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Precision in Practice: Advancing Prostate Cancer Care With PSMA-Directed Radioligand Therapy

Cases and Conversations™: Optimizing Outcomes in PV and ET—Evolving Standards, Symptom Management, and Therapeutic Innovation

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

4th Annual International Congress on Pediatric Oncology

Screening for Type 1 Diabetes and Delaying Its Onset—An Innovative View

ISGIO 2025: Advanced-Stage Colorectal Cancer

ISGIO 2025: Early-Stage Colorectal Cancer

ISGIO 2025: Hepatobiliary Cancers

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia